nad+ and tirzepatide vs Tirzepatide/NAD+ Max Life MD combines GLP-1,

Most participants (63.8%) were women

Based on the STEP 1 clinical study, the semaglutide-treated group reported weight loss beginning with the first assessment after randomization at week 4, reaching its lowest reported weight loss at week 60.[2,4] STEP 1 included 1961 patients randomly assigned to treatment with semaglutide or placebo combined with diet and exercise.[4] Dosage Forms And Strengths Semaglutide is currently available as a clear and colorless injectable solution.[2] The injections come in five different pre-filled, disposable, and single-dose pens[2]: 0.25 mg/0.5 mL 0.5 mg/0.5 mL 1 mg/0.5 mL 1.7 mg/0.5 mL 2.4 mg/0.5 mL Safety Common side effects of semaglutide are gastrointestinal-related.[2,5] These are nausea, vomiting, and diarrhea

While current research focuses predominantly on hepatocytes, potential Kupffer cell modulation in NASH-related inflammation and fibrosis warrants further investigation (78)

These shifts typically stabilize within 46 weeks as your body adjusts to the medication

Because there are no clear guidelines around microdosing, patients should only try it with caution and under medical care